Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.11
34% from low
Exchange
OTC Link
CS
Borrow rate
0.32%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $9.0M | $9.4M | $9.7M | $11.2M | $12.3M | $13.9M | $13.1M |
| Cost of revenue | $5.7M | $4.3M | $3.9M | $3.9M | $4.9M | $4.9M | $5.3M | $9.9M |
| Gross profit | $4.7M | $4.7M | $5.5M | $5.7M | $6.3M | $7.4M | $8.6M | $3.2M |
| Gross margin | 45.2% | 52.1% | 58.3% | 59.4% | 56.3% | 60.2% | 62.2% | 24.6% |
| R&D | $468.6K | $263.4K | $219.5K | $271.7K | $533.7K | $577.4K | $610.7K | $435.84B |
| Operating income | −$290.1K | −$558.3K | $3.2M | $2.6K | $917.2K | −$776.3K | $6.9K | −$956.2K |
| EBITDA | $103.4K | −$353.1K | $3.6M | $631.1K | $1.3M | −$163.1K | $804.2K | −$166.3K |
| Net income | −$844.6K | −$1.9M | −$2.2M | −$2.4M | −$310.7K | −$869.0K | $8.6K | −$908.0K |
| Net margin | -8.1% | -21.8% | -23.7% | -24.6% | -2.8% | -7.1% | 0.1% | -6.9% |
| EPS (diluted) | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 | -0.00 | 0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
RADNOSTIX INC
No one on the platform currently holds INIS.
No tracked institution reports a position in INIS as of their last filing.
No one on the platform has traded INIS yet.
| $4731 |
| — |
| MEDXFMedexus Pharmaceuticals Inc. | $3.10 | +6.63% | $100M | — |
| MILFF1CM Inc. | $0.08 | +0.00% | $9M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.5× sales vs its 2.5× historical median P/S.
Fair value ≈ $0.07 · price $0.07 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$INIS Great piece that accurately captures INIS's current position. So if you want to refresh your understanding of INIS or learn about INIS for the first time, this is essential reading. https://everyticker.com/quote/INIS/analysis/radnostix-s-radioactive-moat-meets-financial-distress-a-0-07-bet-on-nuclear-medicine-s-niche-infrastructure-nasdaq-inis
View on StockTwits ↗$INIS Google the company and you will see this is a real company with real products
View on StockTwits ↗$INIS has now released their 10-K if anybody else was waiting!
View on StockTwits ↗I'm surprised that we haven't seen a 10-K from $INIS yet for 2025. Seems like it is getting kind of overdue, but maybe this is because of how much they were focusing on the DUF6 sale termination. Hopefully will come early in April
View on StockTwits ↗$INIS Last post about this. I wrote my thoughts in a new post that is more complete than these snippets. TLDR: it might still be a good investment, but there are a lot of issues with the balance sheet that need to be addressed: https://www.theinvestmentlog.com/posts/inis/2026-03-19 I think this company will end up being owned by the board unless they find a new entity to acquire DUF6. It should at least help that people know it's for sale now
View on StockTwits ↗$INIS I guess the spin is that now that they aren't selling their DUF6 asset to American Fuel, they can sell it for more money? I hope this works out, but I'm skeptical. We'll see, the market seems to like this news
View on StockTwits ↗$INIS I have also had troubles getting any sort of response from investor relations. A company like this really needs to learn to communicate better with shareholders
View on StockTwits ↗$INIS terminated the asset sale of DUF6. This seems like a much less interesting company when they have this anchor tied to them. Hopefully they can find another buyer now that they have somewhat proven out the process. My concern is that the company is going to wipe out equity holders and end up with the debt holders taking over. Would have been great to get this cash influx so they could clean up the balance sheet
View on StockTwits ↗$INIS My Overall OpinionINIS (Radnostix) shows some positive momentum: revenue growth, margin expansion, and a pivot to high-potential areas like theranostics and medical devices, which align with aging populations and advances in nuclear medicine. The asset sale could inject significant cash (~6x current cash reserves), potentially funding R&D or debt reduction, and the name change signals a clearer healthcare focus. If executed well, this could position it for profitability in a niche market with barriers to entry (e.g., regulatory expertise).However, it's a highly speculative investment. The company is tiny, with razor-thin profits, heavy debt relative to equity, and a history of losses that could recur if supplies falter or regulations tighten. Liquidity is precarious, and the registration revocation adds red flags—reduced transparency could mean hidden problems or just administrative fallout from the rebrand. At $0.09/share, it's cheap, but volatility is high, trading volume low,
View on StockTwits ↗$INIS I'm surprised there hasn't been any news on the DUF6 asset disposal. I am really hoping they can get it buttoned up in March. What will come next for Radnostix?
View on StockTwits ↗$INIS Brilliant piece that captures INIS's situation perfectly. So if you want to update your understanding of INIS or get to know INIS better, this is essential reading. https://everyticker.com/quote/INIS/analysis/international-isotopes-radioactive-moats-meet-operational-meltdown-nasdaq-inis
View on StockTwits ↗$INIS - INTERNATIONAL ISOTOPES INC - 10Q - Updated Risk Factors INIS flags new risks from volatile raw material and energy costs, potential distributor instability, reliance on overseas isotope suppliers vulnerable to geopolitical shifts, ongoing efforts to secure critical isotopes via a new joint venture, and continued supply chain disruptions threatening sales and revenue. #IsotopeIndustry #JointVenture #EnergyCostVolatility #GeopoliticalRisk #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/INIS/10-Q/2025-11-14
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.